- Molecular NameAdapalene
- SynonymAdapaleno [INN-Spanish]; Adapalenum [INN-Latin]
- Weight412.529
- Drugbank_IDDB00210
- ACS_NO106685-40-9
- Show 3D model
- LogP (experiment)7.884
- LogP (predicted, AB/LogP v2.0)7.02
- pkaN/A
- LogD (pH=7, predicted)4.45
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-5.55
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds4
- TPSA46.53
- StatusFDA approved
- AdministrationTopical
- PharmacologyA third-generation topical retinoid primarily used in the treatment of mild-moderate acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions.
- Absorption_valueN/A
- Absorption (description)Absorption of adapalene through human skin is low. Only trace amounts (<0.25 ng/mL) of parent substance have been found in the plasma of acne patients following chronic topical application of adapalene in controlled clinical trials
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolized mainly by O-demethylation, hydroxylation and conjugation, and excretion is primarily by the biliary route.
- Half lifeRanged from 7 to 51 hours, with a mean of 17.2 ± 10.2 hours.
- ExcretionBiliary
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe acute oral toxicity of adapalene in mice and rats is greater than 10 mL/kg. Chronic ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of Vitamin A.
- LD50 (rat)N/A
- LD50 (mouse)N/A